Articles tagged with Cell Therapies
Researchers at the University of Notre Dame have developed a wireless LED device that can be implanted to treat deep-seated cancers. The device, combined with a light-sensitive dye, destroys cancer cells and triggers an immune response against them.
Researchers discuss the critical role of the retinal pigmented epithelium in human vision and its susceptibility to aging. The study highlights the importance of understanding molecular and cellular mechanisms driving age-related pathological changes in vision decline.
A systematic review and meta-analysis of CAR T cell therapy reveals that infections are the main driver of non-relapse mortality in patients. The study analyzed reports from over 7,600 patients across 18 clinical trials and found that infections accounted for half of all reported non-relapse related deaths.
LNP-mRNA therapy faces challenges like targeting, quality control, and safety concerns. Researchers are optimizing dosage, addressing CMC requirements, and enhancing targeting efficiency to improve therapeutic outcomes.
Researchers have identified a novel type of T cell that can recognize and respond to multiple bacterial strains in the gut. This breakthrough finding has significant implications for treating diseases such as cancer and inflammatory bowel disease. The discovery was made by Kazuki Nagashima, winner of the NOSTER & Science Microbiome Prize.
Immunotherapies have revolutionized HCC treatment by enhancing the immune system's ability to recognize and destroy cancer cells. Key approaches include checkpoint inhibitors, targeted therapies, and advanced cellular immunotherapies.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
A new biomarker has been discovered that can help predict which patients with clear cell renal cancer are at higher risk of recurrence. The 15-gene signature was found to be independently associated with worse disease-free survival and disease-specific survival in two large validation datasets.
Researchers at Georgia Tech have developed a method to improve adoptive T-cell therapy using nanowires to deliver therapeutic miRNA to naïve T-cells. This approach retains the cells' naïve state, making them more effective disease fighters when infused back into patients.
Researchers at MD Anderson Cancer Center have identified a small molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), reducing cellular senescence and tissue inflammation. TERT restoration also spurred new neuron formation with improved memory and enhanced neuromuscular function.
Recent research reveals that targeting senescent cells as the cause of aging is not accurate. Instead, these cells have positive health impacts and may pose risks if targeted therapeutically.
Researchers at EPFL have published an open-source project Tabulae Paralytica, providing a comprehensive understanding of spinal cord injury biology. The study identifies specific neurons and genes involved in recovery and proposes a successful gene therapy derived from its discoveries.
Researchers found a link between gut microbiota and Parkinson's disease, revealing reduced B vitamins and intestinal barrier issues. Treatment with B vitamins could alleviate PD symptoms and slow disease progression.
Researchers at Francis Crick Institute develop a new genetic therapy that silences mutated NRAS gene in cells with congenital melanocytic naevus syndrome (CMN), potentially reversing debilitating giant moles. The treatment has shown promising results in mice and could be used to reduce cancer risk in affected children and adults.
Researchers developed an ex vivo gene-editing protocol to treat hereditary tyrosinemia type 1 using liver cell therapy. The study showed robust engraftment and expansion of transplanted gene-edited hepatocytes in recipient mice, correcting disease indicators such as normalized tyrosine, phenylalanine levels.
Scientists at St. Jude Children's Research Hospital discovered that NLRC5 plays a crucial role as an innate immune sensor, triggering PANoptotic cell death. The findings suggest that targeting NLRC5 could lead to therapeutic development for infections, inflammatory diseases, and aging.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
A new detailed analysis of a patient's second cancer after receiving CAR-T therapy provides valuable guidance for clinicians. The study reveals that CAR-T related second cancers can occur, often with lymphomas, and highlights the need for early detection and management.
The study highlights the potential of omics research and AI tools to disentangle the molecular drivers of Alzheimer’s disease. Key findings include the identification of novel biomarkers for early detection and therapeutic targets, as well as the exploration of genetic factors contributing to AD risk and progression.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared to chemotherapy alone in TKI-treated non-small cell lung cancer patients. This treatment may offer a new option for patients with EGFR variant and limited treatment options.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers discover novel suppressive role of Ctdnep1 in osteoclast differentiation and bone resorption, suggesting potential therapeutic targets for treating excessive bone loss. The study reveals that Ctdnep1 functions as a brake on osteoclast cell differentiation.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers at the University of Houston have identified a subset of T cells called CD8-fit that show high motility and serial killing capabilities in patients with clinical responses. These cells were discovered using a patented approach called TIMING, which evaluates cell behavior and movement to identify potential cancer-killing cells.
Researchers review Silibinin's efficacy in managing inflammation, a key factor in tumour development and aging. The molecule may reduce drug-related toxicity and increase therapeutic potential in integrated cancer therapies.
A study published in Radiology found that low-level light therapy increased resting-state functional connectivity in patients with moderate traumatic brain injuries. The treatment showed improved brain connectivity within the first two weeks, but its long-term effects are still unclear.
Researchers at USask have discovered a new peptide that lowers lipid accumulation in human liver cells, offering new avenues for treating metabolic diseases. The finding is hopeful news as there's a lack of new therapies available for these diseases.
The study reveals that FLVCR1 and FLVCR2 transport choline and ethanolamine across cellular membranes, supporting cell growth and stability. This discovery contributes to understanding rare diseases and developing new therapies for patients suffering from severe neurological and muscular disorders.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
Scientists have discovered the transporters responsible for delivering essential nutrients choline and ethanolamine to human cells. The study sheds light on the atomic structure of these transporters and their role in distributing micronutrients throughout the body, providing a foundation for new therapeutic approaches.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
A new study shows that gene therapy delivered by nanocarriers can repair damaged discs and reduce signs of back pain in mice. The treatment, which uses naturally derived nanocarriers to deliver genetic material for a protein key to tissue development, restored structural integrity and function to degenerated discs.
A recent study reveals that a cellular process called transfer Ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance. This breakthrough discovery could help researchers develop new drugs to combat resistance and better tools for studying RNA modifications.
University of Minnesota researchers found that immunotherapy improves CD8+ T-cell responses in older mice, reducing mortality from infections. The treatment, PD1 blockade, enhances the ability of T cells to kill harmful cells infected with a virus.
A new Dartmouth-led study has provided new insights into the therapeutic potential of bacteriophage therapy for treating diseases like cystic fibrosis. Researchers found that respiratory epithelial cells sense and respond to therapeutic phages, and interactions between phages and epithelial cells are heterogenous in nature.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Dana-Farber researchers discovered a molecular complex called PI3Kgamma that supports the survival of certain leukemia cells. The team found that eganelisib, an existing medicine, can inhibit this complex and has shown promise in animal models and clinical trials.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
Researchers at the University of Trento have identified a collection of molecular tools to rewrite DNA, including a compact Cas9 enzyme from the human microbiome. The discovery has potential for gene therapy applications and could speed up the development of therapies for genetic diseases.
The Ottawa Hospital is receiving a $59 million grant to boost Canada's capacity for life-saving biotherapeutics, including vaccines, gene therapies, and cell therapies. The funding will support the construction and operation of a world-class biomanufacturing facility at its new campus.
A massive study identifies new biomarkers for renal cell carcinoma subtypes, improving diagnosis and treatment. The researchers' integrative analysis of proteogenomic datasets reveals molecular features shared by clear cell and non-clear cell RCC tumors, as well as unique features to various subtypes.
A new study found extensive alternative splicing of messenger RNA in untreated multiple sclerosis patients compared to healthy controls. Interferon-ß therapy corrected dysregulated alternative splicing, linking it to future clinical exacerbations.
Researchers found PLS occurs significantly more frequently in unequal AB0 settings, leading to haemolysis and anaemia in patients. Blood group A patients with O transplants are particularly at risk.
A new therapy has been identified that can penetrate the slime protecting drug-resistant bacteria, allowing it to be killed by the body's immune system or antibiotics. The antimicrobial peptide, derived from cow peptides, targets sugar connections in the slime structure, damaging its integrity and allowing entry.
Researchers at the University of Notre Dame found that adding a pre-ketone supplement to an immunotherapy treatment significantly reduced prostate cancer in laboratory settings. The combination therapy made tumors sensitive to immunotherapy, leading to 23% tumor cure rates and dramatic shrinking.
Researchers at the University of Leipzig Medical Center have identified biomarkers associated with the response to CAR T cell therapy in multiple myeloma. These biomarkers enable patients to predict their likelihood of responding well or less well to treatment before initiating therapy.
Researchers developed a gene-based therapy that restored typical cellular function in organoids created from cells of people with Timothy syndrome. The treatment used antisense oligonucleotides to decrease the use of mutated exon 8A and increase reliance on non-affected exon 8, restoring normal calcium channel functioning.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Researchers at Baylor College of Medicine conducted a phase I clinical trial using CAR T cells engineered to target the HER2 protein, which is overexpressed on sarcoma cells. The therapy showed safety and associated with clinical benefit, with improved CAR T expansion and persistence.
Therapeutic phages can detect epithelial cells of the human respiratory tract, eliciting proinflammatory responses. Specific phage properties and airway microenvironment influence these responses.
Researchers at NJIT are developing a hydrogel therapy that prevents viruses like SARS-CoV-2 from attaching to and entering cells. The peptides in the gel form a 'molecular mask' that muffles the virus's action, providing a potential first line of defense against biological threats.